These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 35124800)

  • 1. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
    Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
    J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
    EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning of humoral immunity depending on the types of COVID-19 vaccine.
    Lim SY; Kim JY; Jung J; Yun SC; Kim SH
    Infect Dis (Lond); 2023 Mar; 55(3):216-220. PubMed ID: 36625442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.
    Parry H; Bruton R; Tut G; Ali M; Stephens C; Greenwood D; Faustini S; Hughes S; Huissoon A; Meade R; Brown K; Amirthalingam G; Otter A; Hallis B; Richter A; Zuo J; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e554-e560. PubMed ID: 34401865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
    Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.